Utility of Plasma Circulating mRNA as a Marker to Detect Hepatic Injury

Kudo, Yoshihisa; Ochi, Takashi; Shimada, Hideaki; Ogawa, S.; Shinjo, Keiko

doi:10.1292/jvms.70.993

Cited by 15 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a study was performed that measured the level of gene expression of haptoglobin ( Hp ) in blood and compared it to serum ALT as a marker of liver damage 28 . The group found that Hp gene expression was more sensitive as an indicator of liver damage.…”

Section: Discussionmentioning

confidence: 99%

Genomic indicators in the blood predict drug-induced liver injury

Huang

Shi²,

Zhang

et al. 2010

Pharmacogenomics J

View full text Add to dashboard Cite

Genomic biomarkers for the detection of drug-induced liver injury (DILI) from blood are urgently needed for monitoring drug safety. We used a unique data set as part of the Food and Drug Administration led MicroArray Quality Control Phase-II (MAQC-II) project consisting of gene expression data from the two tissues (blood and liver) to test cross-tissue predictability of genomic indicators to a form of chemically-induced liver injury. We then use the genomic indicators from the blood as biomarkers for prediction of acetaminophen-induced liver injury and show that the cross tissue predictability of a response to the pharmaceutical agent (accuracy as high as 92.1%) is better than, or at least comparable to, that of non-therapeutic compounds. We provide a database of gene expression for the highly informative predictors which brings biological context to the possible mechanisms involved in DILI. Pathway-based predictors were associated with inflammation, angiogenesis, Toll-like receptor signaling, apoptosis and mitochondrial damage. The results demonstrate for the first time and support the hypothesis that genomic indicators in the blood can serve as potential diagnostic biomarkers predictive of DILI.

show abstract

Section: Discussionmentioning

confidence: 99%

Genomic indicators in the blood predict drug-induced liver injury

Huang

Shi²,

Zhang

et al. 2010

Pharmacogenomics J

View full text Add to dashboard Cite

show abstract

“…The plasma circulating albumin mRNA may serve as a molecular marker for hepatic injury using the acute and chronic rat liver fibrosis models [20]. The measurement of plasma circulating albumin mRNA enabled sensitive and early detection of hepatic injury with a large assay window compared with that of plasma ALT activity.…”

Section: Discussionmentioning

confidence: 99%

“…These studies have had a mixed level of success, however, with detection rates of blood ALB mRNA of >100% from patients with HCC [19], cirrhosis, or hepatitis and from healthy controls. The correlation of plasma ALB mRNA concentration with hepatic injury in rats have been reported [20], however, the studies in human is still lacking.…”

Section: Introductionmentioning

confidence: 99%

Circulating Plasma Albumin mRNA as a Predictor of Liver Injury in Chronic Hepatitis C and Hepatocellular Carcinoma

Thabet¹,

Rady²,

Sabawi³

et al. 2011

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

Background: Analysis of circulating nucleic acids in plasma, such as cell free RNA offers an avenue for non invasive monitoring of a variety of physiological and pathological conditions. Aims: Because albumin is the most abundant protein in the body and is synthesized by the liver, the current study was designed to assess plasma albumin mRNA (ALB mRNA), as a non invasive diagnostic marker of liver injury in chronic HCV (CHC) and hepatocellular carcinoma (HCC).Patients and Methods: The study included 65 patients, 31 patients had CHC and 34 were of HCC as well as 25 healthy control subjects. Patients were subjected to clinical examination, abdominal ultrasonography, CT for HCC cases and laboratory investigations including liver function tests, AFP and plasma albumin mRNA by Real Time-PCR.Results: Patients with CHC and HCC have a significant increase in their plasma ALB mRNA than controls; the higher level was in HCC cases. At a cut-off >935 copies/ml, plasma ALB mRNA can discriminate liver diseased from healthy subjects, with a sensitivity of 81.5%, and specificity of 96%, while, elevated serum levels of ALT had a sensitivity of 32.3%, and specificity of 92%. However, at a cut off >20 ng/ml alpha feto protein (AFP) had a sensitivity of 55.9% and sensitivity of 91.2%.in diagnosis of HCC.Conclusion: ALB mRNA in plasma is liver specific; it is increased in liver disease suggesting liver pathology and may be more diagnostically sensitive than alpha-fetoprotein and Alanine aminotransaminase (ALT) serum levels. Thus, future studies should assess if the plasma concentration of ALB mRNA may be used as therapy monitoring.

show abstract

“…These studies have had a mixed level of success, however, with detection rates of blood ALB mRNA of >100% from patients with HCC (Anker &Stroun 2002), cirrhosis, or hepatitis and from healthy controls. The correlation of plasma ALB mRNA concentration with hepatic injury in rats have been reported, however, the studies in human is still lacking (Kudo et al, 2008).…”

Section: ____________________________________________________________mentioning

confidence: 99%

Plasma albumin m RNA as anon invasive Marker to predict liver injury in chronic Hepatitis C and Hepatocellular carcinoma patients

Souaya

El-Hadidi

Mohammed

et al. 2015

Journal of Scientific Research in Science

View full text Add to dashboard Cite

Analysis of circulating nucleic acids in plasma, such as cell free RNA offers an avenue for non-invasive monitoring of a variety of physiological and pathological conditions. Because albumin is the most abundant protein in the body and is synthesized by the liver, the current study was designed to assess plasma albumin mRNA (ALB mRNA), as a noninvasive diagnostic marker of liver injury in chronic HCV (CHC) and hepatocellular carcinoma (HCC). The study included 50 patients, 20 patients had CHC and 20 were of HCC as well as 10 healthy control subjects. Patients were subjected to clinical examination, abdominal ultrasonography, CT for HCC cases and laboratory investigations including liver function tests, AFP and plasma albumin mRNA by Real Time-PCR. Patients with CHC and HCC have a significant increase in their plasma ALB mRNA than controls; the higher level was in HCC cases. ALB mRNA in plasma is liver specific; it is increased in liver disease suggesting liver pathology and may be more diagnostically sensitive than alpha-fetoprotein and Alanine amino transaminase (ALT) serum levels. Thus, future studies should assess if the plasma concentration of ALB mRNA may be used as therapy monitoring.

show abstract

Utility of Plasma Circulating mRNA as a Marker to Detect Hepatic Injury

Cited by 15 publications

References 14 publications

Genomic indicators in the blood predict drug-induced liver injury

Genomic indicators in the blood predict drug-induced liver injury

Circulating Plasma Albumin mRNA as a Predictor of Liver Injury in Chronic Hepatitis C and Hepatocellular Carcinoma

Plasma albumin m RNA as anon invasive Marker to predict liver injury in chronic Hepatitis C and Hepatocellular carcinoma patients

Contact Info

Product

Resources

About